Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann; Luis Paz‐Ares; Reyes Bernabé; Bogdan Żurawski; Sang‐We Kim; Enric Carcereny; Keunchil Park; Aurelia Alexandru; Lorena Lupinacci; Emmanuel de la Mora Jimenez; Hiroshi Sakai; István Albert; A. Vergnenègre; Solange Peters; Konstantinos Syrigos; Fabrice Barlési; Martin Reck; Hossein Borghaei; Julie R. Brahmer; Kenneth J. O’Byrne; William J. Geese; Prabhu Bhagavatheeswaran; Sridhar K. Rabindran; Ravi S. Kasinathan; Faith E. Nathan; Suresh S. Ramalingam

doi:10.1056/nejmoa1910231

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hellmann et al. (2019) studied this question.

synapsesocial.com/papers/6985ef823b00292770426f3d https://doi.org/10.1056/nejmoa1910231

View Full Paper

Ask AI

Bookmark

Share

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading